Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Nivolumab in Advanced Solid Tumors
NCT03735628Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of copanlisib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more (2 arms), sponsored by Bayer. Primary endpoints: Dose Limiting Toxicities and Overall Response Rate up to 26 months. Started Oct 2018; status: completed.
02
Drugs
copanlisib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03735628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735628.